Trump plans generic drug tariffs starting in 2028 to test US onshoring
The Trump administration is planning tariffs on imported generic drugs to take effect in 2028, with a two-year delay meant to give the industry time to adjust. The move reflects Trump's push to bring low-cost drug manufacturing back onshore.
The Trump administration announced plans to impose new tariffs on imported generic drugs, set to take effect in 2028 after a two-year delay designed to give pharmaceutical companies time to adjust their supply chains. The move is part of a broader trade strategy aimed at bringing low-cost drug manufacturing back to US soil.
The generic drug market is currently dominated by producers in countries such as India, and displacing those established suppliers will not be easy. Thin profit margins and complex manufacturing processes make a rapid shift of production to the United States difficult. Industry representatives have warned that any added costs could eventually be passed on to consumers.
The plan is being framed as part of the administration's wider tariff agenda covering pharmaceuticals, semiconductors and other goods considered strategically important. Detailed implementation timelines and possible exemptions are expected to become clearer in the coming months.
Read next
Argentina's trade surplus hits record near $14 billion in first half of 2026
Argentina posted a record trade surplus of nearly $14 billion in the first half of 2026. However, a June dip in exports alongside a rebound in imports has sparked debate among economists over what the shift signals for the broader economy.
Guyana ferry capsize death toll rises to 53 as survivors describe terror
Hungarian prosecutors raid data servers of Orban's Fidesz party, party says
Fed warned banks on cybersecurity but went months without the Anthropic AI model itself
